Abstract
Rituximab, a chimeric monoclonal antibody targeting the CD20 antigen on B lymphocytes, is now the standard treatment for relapsed, low-grade or follicular non-Hodgkin's lymphoma.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD / immunology
-
Antigens, CD20 / immunology
-
Antineoplastic Agents / therapeutic use*
-
B-Lymphocytes / immunology
-
Clinical Trials as Topic
-
Humans
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / immunology
-
Rituximab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD
-
Antigens, CD20
-
Antineoplastic Agents
-
Rituximab